Zepatier Tablet, Film Coated
NDC Package 0006-3074-02
Package Information
Zepatier (elbasvir and grazoprevir) tablets is a medication used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. This formulation utilizes a tablet, film coated delivery system. Marketed by Merck Sharp & Dohme Llc, this product is identified by NDC 0006-3074 and is authorized under FDA application NDA208261.
Identification & Billing
- RxCUI: 1734636 - elbasvir 50 MG / grazoprevir 100 MG Oral Tablet
- RxCUI: 1734642 - Zepatier 50 MG / 100 MG Oral Tablet
- RxCUI: 1734642 - elbasvir 50 MG / grazoprevir 100 MG Oral Tablet [Zepatier]
- RxCUI: 1734642 - Zepatier (elbasvir 50 MG / grazoprevir 100 MG) Oral Tablet
Clinical Specifications
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Cytochrome P450 3A Inhibitors - [MoA] (Mechanism of Action)
- HCV NS3/4A Protease Inhibitors - [MoA] (Mechanism of Action)
- Hepatitis C Virus NS3/4A Protease Inhibitor - [EPC] (Established Pharmacologic Class)
- Hepatitis C Virus NS5A Inhibitor - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 0006 - Merck Sharp & Dohme Llc
- 0006-3074 - Zepatier
- 0006-3074-02 - 2 DOSE PACK in 1 CARTON / 14 TABLET, FILM COATED in 1 DOSE PACK (0006-3074-01)
- 0006-3074 - Zepatier
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0006-3074-02 identifies a specific commercial package of 2 dose pack in 1 carton / 14 tablet, film coated in 1 dose pack (0006-3074-01) of Zepatier, a human prescription drug labeled by Merck Sharp & Dohme Llc. This tablet, film coated is formulated for oral use and contains elbasvir; grazoprevir anhydrous as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Merck Sharp & Dohme Llc on January 28, 2016. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. Elbasvir and grazoprevir work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. This product may also be used with certain other medications (such as ribavirin). Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis) or liver cancer. It is not known if this treatment can prevent you from passing the virus to others. Do not share needles, and practice "safer sex" (including the use of latex condoms) to lower the risk of passing the virus to others.
How is this Merck Sharp & Dohme Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00006307402. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 2 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.